Simvastatin reduces circulating plasminogen activator inhibitor 1 activity in volunteers with the metabolic syndrome

Long Wang, Jason Rockwood, Danielle Zak, Sridevi Devaraj, Ishwarlal Jialal

Research output: Contribution to journalArticlepeer-review

10 Scopus citations


Background: The Metabolic Syndrome (MS) confers an increased risk for diabetes and cardiovascular disease. We previously showed that simvastatin has concomitant benefits in reducing low-density lipoprotein (LDL)-cholesterol and inflammation in MS subjects. The levels of plasminogen activator inhibitor 1(PAI-1), soluble P-selectin (sP-selectin), and soluble CD40 ligand (sCD40L) play an important role in the development and progression of atherosclerosis. Their levels are increased in the MS. The current study was to investigate the effects of simvastatin on PAI-1, sP-selectin, and sCD40 ligand. Methods: Fifty subjects with MS were randomized into either placebo or simvastatin (40 mg/day) group for 8 weeks. Blood samples were obtained at baseline and at the end of the study. PAI-1 activity and sP-selectin and sCD40L levels were measured by enzyme-linked immunosorbent assay (ELISA). Results: There was no baseline difference in any of the parameters studied. Compared to baseline, simvastatin significantly reduced (P < 0.05) the circulating PAI-1 activity (24.3 ± 5.2 IU/mL at baseline vs. 21.4 ± 3.9 IU/mL after 8 weeks of treatment). Simvastatin did not alter (P < 0.05) the levels of sP-selectin (111.4 ± 35.9 ng/mL at baseline vs. 118.5 ± 71.2 ng/mL after 8 weeks) or sCD40L (2.0 ± 1.6 ng/mL at baseline vs. 1.5 ± 1.0 ng/mL after 8 weeks). Conclusion: Our data indicate that simvastatin therapy has significant effects on the fibrinolytic system in MS subjects as evidenced in a reduction in PAI-1 activity.

Original languageEnglish (US)
Pages (from-to)149-152
Number of pages4
JournalMetabolic Syndrome and Related Disorders
Issue number2
StatePublished - Jun 1 2008

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism


Dive into the research topics of 'Simvastatin reduces circulating plasminogen activator inhibitor 1 activity in volunteers with the metabolic syndrome'. Together they form a unique fingerprint.

Cite this